Lisa M. Holle, PharmD, BCOP, FHOPA
Lisa M. Holle, PharmD, BCOP, FHOPA is an assistant clinical professor, University of Connecticut School of Pharmacy, Storrs, Conn.
Atezolizumab for Urothelial Carcinoma and Non-Small Cell Lung Cancer
Here: an overview of atezolizumab, the first new drug in two decades for bladder cancer and now approved for NSCLC.
Ixazomib for multiple myeloma
FDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone
The role of the community pharmacy team in assisting patients receiving oral anticancer medications
The role of the community pharmacy team in assisting patients receiving oral anticancer medications
The goal of this activity is to educate the community pharmacy team about oral anticancer medications.
FDA approves trifluridine/tipiracil for colorectal cancer
Lonsurf is a new, orally administered cytotoxic drug for the treatment of patients with metastatic colorectal cancer.
FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting
Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.

Poll